News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
717,875 Results
Type
Article (42582)
Company Profile (436)
Press Release (674857)
Multimedia
Podcasts (80)
Webinars (13)
Section
Business (209434)
Career Advice (2047)
Deals (36069)
Drug Delivery (104)
Drug Development (83712)
Employer Resources (173)
FDA (16490)
Job Trends (15126)
News (353838)
Policy (33202)
Tag
Academia (2653)
Accelerated approval (6)
Adcomms (24)
Allergies (88)
Alliances (51078)
ALS (99)
Alzheimer's disease (1440)
Antibody-drug conjugate (ADC) (147)
Approvals (16471)
Artificial intelligence (279)
Autoimmune disease (26)
Automation (16)
Bankruptcy (372)
Best Places to Work (11849)
BIOSECURE Act (19)
Biosimilars (107)
Biotechnology (330)
Bladder cancer (83)
Brain cancer (27)
Breast cancer (299)
Cancer (2378)
Cardiovascular disease (191)
Career advice (1713)
Career pathing (30)
CAR-T (161)
Cell therapy (457)
Cervical cancer (20)
Clinical research (67964)
Collaboration (900)
Company closure (2)
Compensation (566)
Complete response letters (24)
COVID-19 (2657)
CRISPR (47)
C-suite (262)
Cystic fibrosis (106)
Data (2338)
Decentralized trials (2)
Denatured (29)
Depression (52)
Diabetes (280)
Diagnostics (6452)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (112)
Drug shortages (26)
Duchenne muscular dystrophy (103)
Earnings (88608)
Editorial (44)
Employer branding (21)
Employer resources (147)
Events (116473)
Executive appointments (759)
FDA (17874)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (802)
Gene editing (119)
Generative AI (20)
Gene therapy (339)
GLP-1 (756)
Government (4533)
Grass and pollen (4)
Guidances (150)
Healthcare (19198)
Huntington's disease (25)
IgA nephropathy (30)
Immunology and inflammation (137)
Indications (30)
Infectious disease (2805)
Inflammatory bowel disease (150)
Inflation Reduction Act (11)
Influenza (53)
Intellectual property (99)
Interviews (316)
IPO (16827)
IRA (44)
Job creations (3716)
Job search strategy (1454)
Kidney cancer (10)
Labor market (43)
Layoffs (509)
Leadership (18)
Legal (8017)
Liver cancer (77)
Lung cancer (332)
Lymphoma (158)
Machine learning (9)
Management (58)
Manufacturing (332)
MASH (76)
Medical device (13551)
Medtech (13556)
Mergers & acquisitions (19807)
Metabolic disorders (738)
Multiple sclerosis (84)
NASH (19)
Neurodegenerative disease (105)
Neuropsychiatric disorders (33)
Neuroscience (2027)
NextGen: Class of 2025 (6762)
Non-profit (4565)
Now hiring (40)
Obesity (394)
Opinion (224)
Ovarian cancer (82)
Pain (97)
Pancreatic cancer (89)
Parkinson's disease (158)
Partnered (21)
Patents (244)
Patient recruitment (117)
Peanut (47)
People (58881)
Pharmaceutical (86)
Pharmacy benefit managers (20)
Phase I (21352)
Phase II (29981)
Phase III (22174)
Pipeline (1369)
Policy (156)
Postmarket research (2613)
Preclinical (9173)
Press Release (67)
Prostate cancer (111)
Psychedelics (37)
Radiopharmaceuticals (264)
Rare diseases (409)
Real estate (6042)
Recruiting (66)
Regulatory (22861)
Reports (47)
Research institute (2433)
Resumes & cover letters (352)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (78)
Series A (141)
Series B (93)
Service/supplier (11)
Sickle cell disease (58)
Special edition (19)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3767)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (48)
The Weekly (49)
Vaccines (720)
Venture capitalists (44)
Weight loss (257)
Women's health (38)
Worklife (17)
Date
Last 7 days (950)
Last 30 days (3066)
Last 365 days (33393)
2025 (12017)
2024 (36347)
2023 (41069)
2022 (52330)
2021 (56799)
2020 (54985)
2019 (47552)
2018 (35785)
2017 (33087)
2016 (32425)
2015 (38484)
2014 (32250)
2013 (27212)
2012 (29364)
2011 (30012)
2010 (28190)
Location
Africa (741)
Alabama (59)
Alaska (7)
Arizona (241)
Arkansas (14)
Asia (39387)
Australia (6549)
California (6517)
Canada (2074)
China (548)
Colorado (278)
Connecticut (292)
Delaware (159)
Europe (86153)
Florida (950)
Georgia (213)
Idaho (57)
Illinois (566)
India (25)
Indiana (322)
Iowa (12)
Japan (173)
Kansas (109)
Kentucky (25)
Louisiana (12)
Maine (62)
Maryland (947)
Massachusetts (4928)
Michigan (226)
Minnesota (408)
Mississippi (2)
Missouri (82)
Montana (29)
Nebraska (25)
Nevada (67)
New Hampshire (67)
New Jersey (1822)
New Mexico (30)
New York (1831)
North Carolina (1056)
North Dakota (8)
Northern California (2839)
Ohio (211)
Oklahoma (14)
Oregon (38)
Pennsylvania (1437)
Puerto Rico (13)
Rhode Island (34)
South America (1115)
South Carolina (25)
South Dakota (1)
Southern California (2442)
Tennessee (105)
Texas (965)
United States (24522)
Utah (191)
Virginia (156)
Washington D.C. (66)
Washington State (585)
West Virginia (3)
Wisconsin (57)
717,875 Results for "y mabs therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
May 7, 2025
·
2 min read
Press Releases
Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)
May 7, 2025
·
7 min read
Press Releases
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
March 3, 2025
·
5 min read
Business
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
Y-mAbs Therapeutics, Inc. today announced that Chief Financial Officer, Bo Kruse, has notified the Company of his resignation.
March 14, 2024
·
6 min read
Press Releases
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
March 5, 2025
·
21 min read
Business
Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer
Y-mAbs Therapeutics, Inc. announced the appointment of Norman LaFrance, M.D. as Chief Development Officer.
June 5, 2024
·
7 min read
Press Releases
Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference
February 6, 2025
·
2 min read
Pharm Country
Y-mAbs to Present at 2024 ASCO Annual Meeting
Y-mAbs Therapeutics, Inc. announced the acceptance of four abstracts at the 2024 American Society of Clinical Oncology Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL.
April 25, 2024
·
8 min read
Press Releases
Y-mAbs Provides Strategic Business Update and 2025 Priorities
January 13, 2025
·
10 min read
Press Releases
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
April 28, 2025
·
8 min read
1 of 71,788
Next
